Liquidia director Stephen Bloch sells $6.28m in LQDA stock

Stephen M. Bloch, a director at Liquidia Corp (), sold a total of 78,596 shares of common stock across multiple transactions on July 20 and July 21, 2026. The total value of these sales amounted to approximately $6,285,250. The prices for these transactions ranged from $79.5518 to $80.6576 per share on a weighted average basis. The timing of these sales is notable as LQDA stock has surged 390% over the past year and is currently trading near its 52-week high of $89.51, according to InvestingPro data, which shows the stock is fairly valued relative to its Fair Value estimate.

On July 20, Mr. Bloch sold 3,596 shares at a weighted average price of $79.5518 per share. These shares were sold in a price range of $79.50 to $79.78. Following this transaction, 776,477 shares were beneficially owned indirectly.

The following day, July 21, Mr. Bloch conducted two separate sales. He first sold 74,444 shares at a weighted average price of $79.9841 per share, with individual transaction prices ranging from $79.50 to $80.45. Later on the same day, another 556 shares were sold at a weighted average price of $80.6576, with prices for individual transactions between $80.51 and $80.69. After these transactions, 701,477 shares were beneficially owned indirectly.

The securities are held indirectly by Canaan VIII L.P. Stephen M. Bloch disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest, if any, through his ownership in Canaan Partners VIII LLC, which is the sole general partner of Canaan LP. The Canaan Entities maintain a communications-screen policy regarding the issuer’s securities, and Mr. Bloch did not participate in the investment decision for these sales. For deeper insights into LQDA’s valuation and performance, InvestingPro offers a comprehensive Pro Research Report covering this and 1,400+ other US equities.

In other recent news, Liquidia Corporation’s earnings and revenue developments have caught the attention of investors. BofA Securities has downgraded Liquidia’s stock rating from Buy to Neutral, although it raised the price target to $79, citing a balanced risk-reward profile after the stock’s recent gains. The firm also increased its peak sales estimate for Liquidia’s drug, Yutrepia, to $2.2 billion due to its successful launch. Additionally, Liquidia is set to join the , effective June 22, as announced by the company. This inclusion is based on criteria such as market capitalization, liquidity, and profitability.

H.C. Wainwright has raised its price target for Liquidia to $75, maintaining a Buy rating, following a Supreme Court ruling involving Hikma Pharmaceuticals that could positively impact Liquidia’s legal case. Raymond James also reiterated a Strong Buy rating with a $68 price target, highlighting the favorable implications of the same court decision. These developments reflect a period of significant activity for Liquidia, attracting attention from multiple analyst firms.